Michael Grunebaum
Michael F. Grunebaum is an American psychiatrist. He graduated from Harvard College for his bachelor's degree (1983) and Harvard Medical School for his medical degree (1991). He has worked at the New York State Psychiatric Institute and in private practice in Manhattan. He is also an associate professor of psychiatry at Columbia University Medical School.[1] His research is in the area of mood disorders and suicidal behavior.[1] Several of his research papers are highly cited according to Google Scholar.[2]
Education and career
[edit]Grunebaum graduated magna cum laude from Harvard College in 1983 and earned his medical degree from Harvard Medical School in 1991.[3] He completed his psychiatric residency at the Payne Whitney Psychiatric Clinic of the New York Hospital-Cornell Medical Center in 1995, followed by a Public Psychiatry Fellowship at Columbia University.[4] In addition to his institutional research and teaching roles, he maintains a private psychiatric practice in Manhattan.[3]
Research
[edit]Grunebaum's research primarily focuses on the clinical and biological factors influencing major depressive disorder, bipolar depression, and suicide risk.[3] Funded by grants from the National Institute of Mental Health (NIMH), his work includes investigating rapid-acting pharmacological interventions for treatment-resistant depression.[4]
He is particularly known for leading clinical trials assessing the efficacy of subanesthetic ketamine infusions to rapidly reduce acute suicidal ideation compared to active controls like midazolam.[5][6]
References
[edit]- 1 2 Columbia University Medical Center: Michael F. Grunebaum, MD (accessed 13 February 2016)
- ↑ A Google Scholar search as of February 2016 found citations of 440, 277, 191, 187, 163, 125 for scholarly articles co-authored by Michael F. Grunebaum.
- 1 2 3 "Michael F. Grunebaum, MD". Columbia University Department of Psychiatry. Retrieved 18 July 2026.
- 1 2 "Raising the Rail: Architectural Responses to Suicide by Height". AIA New York. Retrieved 18 July 2026.
- ↑ Grunebaum, MF; Ellis, SP; Li, S; Oquendo, MA; Mann, JJ (2018). "Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial". The American Journal of Psychiatry. 175 (4): 327–335. doi:10.1176/appi.ajp.2017.17060647. PMC 5880701. PMID 29202655.
- ↑ "Michael F Grunebaum". Google Scholar. Retrieved 18 July 2026.